PL372761A1 - Proleki cyjanoguanidynowe - Google Patents

Proleki cyjanoguanidynowe

Info

Publication number
PL372761A1
PL372761A1 PL03372761A PL37276103A PL372761A1 PL 372761 A1 PL372761 A1 PL 372761A1 PL 03372761 A PL03372761 A PL 03372761A PL 37276103 A PL37276103 A PL 37276103A PL 372761 A1 PL372761 A1 PL 372761A1
Authority
PL
Poland
Prior art keywords
cyanoguanidine
prodrugs
cyanoguanidine prodrugs
Prior art date
Application number
PL03372761A
Other languages
English (en)
Inventor
Ernst Torndal Binderup
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of PL372761A1 publication Critical patent/PL372761A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03372761A 2002-05-17 2003-05-15 Proleki cyjanoguanidynowe PL372761A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38085602P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
PL372761A1 true PL372761A1 (pl) 2005-08-08

Family

ID=29550027

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372761A PL372761A1 (pl) 2002-05-17 2003-05-15 Proleki cyjanoguanidynowe

Country Status (15)

Country Link
US (1) US20060014804A1 (pl)
EP (1) EP1507759A1 (pl)
JP (1) JP2005531560A (pl)
KR (1) KR20040111626A (pl)
CN (1) CN1662502A (pl)
AU (1) AU2003223932A1 (pl)
BR (1) BR0309988A (pl)
CA (1) CA2484671A1 (pl)
IL (1) IL164986A0 (pl)
IS (1) IS7563A (pl)
MX (1) MXPA04011324A (pl)
NO (1) NO20045373L (pl)
PL (1) PL372761A1 (pl)
RU (1) RU2004136989A (pl)
WO (1) WO2003097602A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100503570C (zh) * 2002-05-17 2009-06-24 利奥制药有限公司 氰基胍前药
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US7262334B2 (en) * 2002-11-13 2007-08-28 Regents Of The University Of Minnesota Catalytic partial oxidation of hydrocarbons
CA2594508C (en) * 2004-12-22 2013-10-01 Leo Pharma A/S Cyanoguanidine compounds
CA2701071C (en) 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US20110009446A1 (en) * 2008-01-11 2011-01-13 Nektar Therapeutics Oligomer-guanidine class conjugates
JP5688367B2 (ja) 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブTopoTarget A/S 新規なウレアおよびチオウレア誘導体
JP5580339B2 (ja) 2009-02-06 2014-08-27 ティエンジン ホーメイ バイオ−テック カンパニー, リミテッド ピリジルシアノグアニジンを含む薬物組成物、該組成物の製造方法及び応用
WO2011006988A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
SG11201903013SA (en) 2016-10-18 2019-05-30 Seattle Genetics Inc Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
EP3615081A1 (en) * 2017-04-27 2020-03-04 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases

Also Published As

Publication number Publication date
WO2003097602A1 (en) 2003-11-27
IS7563A (is) 2004-11-29
IL164986A0 (en) 2005-12-18
RU2004136989A (ru) 2005-06-27
EP1507759A1 (en) 2005-02-23
MXPA04011324A (es) 2005-02-17
CA2484671A1 (en) 2003-11-27
JP2005531560A (ja) 2005-10-20
BR0309988A (pt) 2005-02-22
US20060014804A1 (en) 2006-01-19
KR20040111626A (ko) 2004-12-31
CN1662502A (zh) 2005-08-31
NO20045373L (no) 2004-12-08
AU2003223932A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
HK1212678A1 (zh) 雙氰胺前體藥物
GB0306907D0 (en) Boireductively-activated prodrugs
AU2003266227A8 (en) Crossmember
AU2003249738A8 (en) Ostoscope
AU2003297193A8 (en) Meta-web
AP2004003119A0 (en) Substituted hydroxyethylamines
AU2003252028A8 (en) Heterodiamondoids
IL166740A0 (en) Substituted heterocyclylpyrimidines
AU2003279495A8 (en) Alert-modeling
DE50303619D1 (en) Reibschweissvorrichtung
PL372761A1 (pl) Proleki cyjanoguanidynowe
SI1487778T1 (sl) Substituirani 4-aminocikloheksanoli
EP1585750A4 (en) NARCISTATIN-BASED PRODRUGS
AU2003264900A8 (en) Cast-cutter
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
DE50304964D1 (en) Handhobelmaschine
AU2003262681A8 (en) Hemo-aide
AU2003233238A8 (en) Fap-activated anti-tumor prodrugs
DE10392833D2 (en) Geotextilie
PL377325A1 (pl) Podstawione benzodioksepiny
AU2003240435A8 (en) Pna prodrugs
GB0314996D0 (en) Prodrugs
AU3399P (en) Kosciuszko xTriticosecale
AU2328P (en) Archley Arctotis fastuosa
CA94955S (en) Handleset

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)